NTRK1 and cancer: Like other receptor tyrosine kinases, wild-type ALK is activated by the binding of its ligand (such as augmentor α), whereas, mutant ALK is located in the cytosol and is constitutively activated in many cancer cells, such as anaplastic large cell lymphoma, in a ligand-independent manner [174,175].